AHA Coding Clinic® for HCPCS - 2022 Quarter 4; For Your Information
Boostrix expanded approval
Approval change for tetanus, diphtheria toxoids and acellular pertussis vaccine Pertussis is a respiratory illness also known as whooping cough. On October 7, 2022, the FDA expanded its approval of the Boostrix vaccine (Tetanus, diphtheria toxoids and acellular pertussis) from protecting an individual from pertussis during pregnancy to now include vaccine administration during the third trimester of pregnancy in order to prevent pertussis in infants 2 months of age and younger. Infants under 2 months of age are most at risk for serious pertussis illness and death since they are too young to receive a pertussis vaccine series...
Subscribe or sign in to view the full article.
Article Overview
This article explains a vaccine approval update affecting maternal immunization guidance and the related medical coding context for reporting the product and administration services. It is intended for coding and billing professionals, clinicians, and compliance staff who need to understand how the change fits into routine vaccine reporting and documentation workflows.
Why This Topic Matters
Policy and approval updates for immunizations can affect how services are documented and reported, especially when they involve pregnancy, infant protection, and vaccine administration coding.
What You Will Learn
- What approval change was made for the Boostrix vaccine
- How the update relates to maternal vaccination timing
- Which broad CPT coding areas are mentioned for the vaccine product and administration reporting
- Why the change is clinically relevant for infant pertussis prevention
Who Should Read This
- Medical coders
- Billers
- Clinical documentation staff
- Obstetric and maternal care teams
- Compliance professionals
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com